USPTO grants patent for LexisNexis PatentSight

Posted by LexisNexis PatentSight team on Sep 9, 2019 2:56:14 PM

PatentSight is proud to announce that our patent analytics software is now a patent protected Intellectual Property. In August, 2019, the USPTO officially granted Nils Omland, our founder and CEO, with a patent for the PatentSight Business Intelligence software solution. Back in 2018, when LexisNexis® acquired PatentSight, this patent was still undergoing review. The granting of this patent makes our SaaS offering, officially, one of its kind.

Read More

Tags: Technology, Science, Patent Analysis, Patent Valuation, Patent Asset Index, Patent Quality, patent


Innovation in merger analysis - How the EU Commission evaluated the case of Bayer-Monsanto

Posted by Carsten Guderian and Nabu Xavier on Sep 4, 2019 3:03:21 PM

In September 2016, the German drugs and chemicals group Bayer announced its intention to acquire the multinational Monsanto, known for its Roundup herbicide and GMOs. This merger would produce the world’s most powerful company in the seed and pesticide industry. On 21 March 2018 the EU commission released a Press Release announcing their approval of the acquisition of Monsanto by Bayer. The merger was approved on the conditional divestiture of an extensive remedy package, which addresses the parties' overlaps in seeds, pesticides and digital agriculture. It is for determining such inconspicuous aspects of a merger, like technology overlap, that the EU commission relied on the LexisNexis® PatentSight® database and our award-winning Business Intelligence software solution.

Read More

Tags: Technology, Science, Mergers and Acquisitions, Patent Analysis, Patent Valuation, Patent Asset Index, Patent Quality, M&A, Merger Evaluation, EU Commission, Competition Control


China in Rare Earth Elements - top supplier, major patent developer, yet portfolio strength still a concern

Posted by William Mansfield on Sep 4, 2019 10:33:56 AM

From recent news reports it became clear that China accounts for almost 90% of the world’s production and supply of the so-called Rare Earth Elements (REE). These are a group of 17 elements that are not commonly found in the earth's surface. For e.g. Scandium, one of the rare earth elements, is heavily used in manufacturing parts for the aerospace industry. Similarly, these elements have varied and extremely specific uses, for which, at least for the time-being, no viable substitutes can be sourced. We used our excellent patent database and scientifically proven metrics to analyze the current situation around rare earth elements from a patent quality point of view to identify possible opportunities and threats in this business.

Read More

Tags: Technology, Science, Patent Analysis, Patent Valuation, Patent Asset Index, Patent Quality, Rare earth metals, China, USA, rare earth elements


Israeli Innovation Leader - A patent analysis

Posted by William Mansfield on Mar 12, 2019 9:32:59 AM

Recently, we applied the PatentSight Patent Asset Index methodology to gain a new insight into which of Israel’s research bodies are leading in innovation. The index assesses the strength of an organization’s patent portfolio in terms of quality of patents held measured by TechnologyRelevance™ and Market Coverage ™. So, what did we find?

 

Read More

Tags: Science, Patent Analysis, Innovation, Patent Asset Index


Patent analysis reveals opportunities and concerns around the Bristol-Myers Squibb/Celgene merger

Posted by William Mansfield on Feb 25, 2019 4:46:01 PM

In January of this year, U.S. pharmaceutical manufacturers Bristol-Myers Squibb (BMS) and Celgene Corporation announced they had entered into a definitive merger agreement for BMS to acquire Celgene.

The stated aim of the merger is to create ‘a premier innovative biopharma company’ with a particular focus on building an expanded offering in the cancer and immunotherapy space. If completed, the transaction is expected to cost $74 billion in a cash and stock deal, whereby Celgene shareholders will receive 1.0 BMS share as well as $50 in cash for each share of Celgene.

Our analysis of the two firms’ respective patent portfolios provides insight into how this merger would affect the U.S. pharma market. For this analysis, we employed our Patent Asset IndexTM methodology, which scientifically assesses patent families against Key Performance Indicators of Technology RelevanceTM and Market CoverageTM.

Read More

Tags: Science, Mergers and Acquisitions, Patent Analysis, Patent Asset Index


Application fields and active protection - A closer look at the top 20 Universities and Research centers

Posted by William Mansfield on Jan 11, 2019 3:53:59 PM

For a study commissioned by IAM, PatentSight has taken a closer look at the patenting activity of leading universities and research centers based on the Patent Asset IndexTM.

Read More

Tags: Technology, Science, Innovation, Patent Asset Index


The Top 20 Most Innovative Chinese Universities

Posted by LexisNexis PatentSight team on Nov 12, 2018 1:15:01 PM

 跳转到简体中文 (jump to Simplified Chinese):

中国高校创新力前20强

 

Today, LexisNexis published a ranking of China’s top 20 most innovative universities based on their patent assets. Analysts at LexisNexis have identified these top universities as sorted by the Patent Asset Index™.

 

Read More

Tags: Technology, Science, Patent Valuation, Innovation, Patent Asset Index


PatentSight is now part of LexisNexis® IP

Posted by Nils Omland on May 16, 2018 2:32:17 PM

You may have seen our recent press release but I wanted to personally express my excitement over the recent acquisition by LexisNexis® IP. We anticipate that as a result of this acquisition, we will be able to make significant enhancements to our product.

With added content, financial resources, and a broader customer base we will significantly accelerate our development. In particular, the advent of powerful self-learning algorithms often described as “artificial intelligence” is a great opportunity to reach the next breakthrough in patent analytics. We are thrilled to leverage our competence in high quality data and reliable science-based algorithms to continue leading the field with advanced tools that offer unique and reliable business insights.

Rest assured, many things you value about PatentSight will not change. PatentSight will continue under the leadership of myself and my team in the same offices in Bonn, Germany. All PatentSight employees will be retained and your current points of contact will not change. Our much-praised Consulting & Support Team will continue to serve you directly. The name of the product will change slightly to LexisNexis PatentSight.

We look forward to our continued relationship. Please contact me, Björn Ulmer or your main contact in the business development team if you have any additional questions.

Read More

Tags: Technology, Science, Mergers and Acquisitions, IP Data Quality, Patent Analysis, Patent Valuation, Innovation, Patent Asset Index